Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-02. Numbers and descriptions here follow the published literature rather than marketing material.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Chemical modification of wood. Wood and Fiber Sci., 26(2):270-280. Langrish, T.A.G. and Walker, J.C.F. (1993). Transport Processes in Wood. In: Walker, J.C.F. Primary Wood Processing. Chapman and Hall, London. pp121–152. Panshin, A.J. and de Zeeuw, C. (1970). Textbook of Wood Technology. Volume 1, Third Edition. McGraw-Hill, New York, 705 p. Pordage, L.J. and Langrish, T.A.G. (1999). Simulation of the effect of air velocity in the drying of hardwood timber. Drying Technology - An International Journal, 17(1&2):237-256. Rasmussen, E.F. (1988). Forest Products Laboratory, U.S. Department of Agriculture. (ed.). Dry Kiln Operators Manual. Hardwood Research Council. Rowell, R.M. (1983). Chemical modification of wood. Forest Product Abstract, 6(12):363-382. Rowell, R.M. (1991). Chemical Modification of Wood. In: Hon, D.N.-S and Shiraishi, N. (eds), Wood and Cellulosic Chemistry. pp. 703–756. Marcel Dekker, Inc., New York. Siau, J.F. (1984). Transport processes in wood. Springer-Verlag, New York. 245p. Sjostrom, E. (1993). Wood Chemistry: Fundamentals and Applications. Academic Press Limited, London. 293p. Skaar, C. (1988). Wood Water Relations. Springer-Verlag, New York. 283p. Stamm, A. J. (1964). Wood and Cellulose Science. Ronald Press, New York. 509p. Standard Australia (2000). Timber - Classification into Strength Groups. Australian/New Zealand Standard (AS/NZS) 2878. Sydney. 36p. Standard Australia (2001). Timber - Assessment of Drying Quality. Australian/New Zealand Standard (AS/NZS) 4787. Sydney. 24p. Strumillo, C. and Kudra, T. (1986).
Askari had shaken the South African government's confidence in its ability to retain the military advantage indefinitely in Angola. Heavier and more sophisticated weapons were being used, the rate of casualties had increased, and the air superiority that had accounted for many of the SADF's previous successes was diminishing. Nor was Botha and his cabinet certain of continued political and diplomatic support from the US, which had chosen to abstain rather than exercise its veto with regard to UN Security Council Resolution 546. The Reagan administration perceived that both Angola and South Africa had grown weary of the war and were more susceptible to pressure for a ceasefire and mutual disengagement. American diplomats offered to mediate peace talks accordingly, and on 13 February South African and Angolan officials met for the first time in Lusaka. Three days later, South Africa announced that it would withdraw its expeditionary forces from Cunene Province by the end of March, provided the Angolans agreed to prevent PLAN from taking advantage of the situation to infiltrate South West Africa. The Angolan government pledged to restrain PLAN and MK, and to prohibit any movement of Cuban troops southward towards the border. These respective commitments were formalised as the Lusaka Accords. FAPLA and the SADF agreed to set up a Joint Monitoring Commission (JMC) to police the disengagement. Under the JMC, joint South African and Angolan patrols were carried out along six hundred kilometres of the border.
===== Sliding-rebinding model ===== The sliding-rebinding model differs from the allosteric model in that the allosteric model posits that only one binding site exists and can be altered, but the sliding-rebinding model states that multiple binding sites exist and aren't changed by EGF extension. Rather, in the bent conformation which is favored at low applied forces, the applied force is perpendicular to the line of possible binding sites. Thus, when the association between ligand and lectin domain is interrupted, the bond quickly dissociates. At larger applied forces, however, the protein is extended and the line of possible binding sites is aligned with the applied force, allowing the ligand to quickly re-associate with a new binding site after the initial interaction is disrupted. With multiple binding sites, and even the ability to re-associate with the original binding site, the rate of ligand dissociation would be decreased as is typical of catch bonds.
Electron-mediated heteronuclear J-couplings (spin–spin couplings) are field independent, producing clusters of two or more frequencies separated by several Hz, which are more easily observed in a fundamental resonance of about 2 kHz."Indeed it appears that enhanced resolution is possible due to the long spin relaxation times and high field homogeneity which prevail in EFNMR." Chemical shifts of several ppm are clearly separated in high field NMR spectra, but have separations of only a few millihertz at proton EFNMR frequencies, so are usually not resolved.
Sources: en.wikipedia.org
Boletus edulis (English: cep, penny bun, porcino) is a basidiomycete fungus, and the type species of the genus Boletus. It is prized as an edible mushroom. The fungus produces spore-bearing fruit bodies above ground in summer and autumn. The fruit body has a large brown cap which can reach 30 cm (12 in) in diameter and 3 kg (6 lb 10 oz) in weight. Like other boletes, it has tubes extending downward from the underside of the cap, rather than gills; spores escape at maturity through the tube openings (pores). The pore surface of the fruit body is whitish when young, aging to a greenish-yellow. The stout stipe (or stem) is white or yellowish, up to 25 cm (10 in) tall and 7 cm (3 in) thick, and partially covered with a raised network pattern (reticulations). The fungus grows in deciduous and coniferous forests and tree plantations, forming symbiotic ectomycorrhizal associations with living trees by enveloping the tree's underground roots with sheaths of fungal tissue. Widely distributed in the Northern Hemisphere across Eurasia and North America, it does not occur naturally in the Southern Hemisphere but has been introduced to it. Several closely related European mushrooms formerly thought to be varieties or forms of B. edulis have been shown using molecular phylogenetic analysis to be distinct species, while others previously classified as separate species are conspecific with B. edulis. The western North American species commonly known as the California king bolete (B. edulis var. grandedulis) is a large, darker-coloured variant first formally identified in 2007. B.
== Taxonomy == This species was first formally described in 1753 by Carl Linnaeus who gave it the name Cassia occidentalis in Species Plantarum from specimens collected in Jamaica. In 1829, Link transferred the species to the genus Senna as S. occidentalis in his Handbuch zur Erkennung der nutzbarsten und am häufigsten vorkommenden Gewachse. The specific epithet (occidentalis) means "western".
A regulatory enzyme is an enzyme in a biochemical pathway which, through its responses to the presence of certain other biomolecules, regulates the pathway activity. This is usually done for pathways whose products may be needed in different amounts at different times, such as hormone production. Regulatory enzymes exist at high concentrations (low Vmax) so their activity can be increased or decreased with changes in substrate concentrations
Another possible example is the Second Congo War (1998–2003) even though it was only waged on one continent. It involved nine nations and led to ongoing low-intensity warfare despite official peace and the first democratic elections in 2006. It has been referred to as "Africa's World War". Similarly, other historians suggest even earlier conflicts to be world wars. For example, Russian ethnologist L. N. Gumilyov called the Byzantine–Sasanian War of 602–628 "the World War of the 7th century" because it evolved into a war between the fourfold informal alliance of the Chinese Empire, the Western Turkic Khaganate, the Khazars, and the Byzantine Empire against a triple union of the Sasanian Empire, the Avars, and the Eastern Turkic Khaganate, with proxy conflicts in Afro-Eurasia (like the Aksumite–Persian wars) and across the Old World.
== Misery Index == Bloomberg's Misery Index 2019 ranked Thailand as the world's "least miserable" economy. The index is calculated as the sum of a country's inflation and unemployment rates. In 2019, Bloomberg again took a swipe at Thai statistics: "Thailand again claimed the title of the 'least miserable' economy, though the government’s unique way of tallying unemployment makes it less noteworthy...." Singapore was ranked as the third "least miserable" and Malaysia, sixth. Bloomberg's Misery Index 2017 ranked Thailand 65 of 65 nations (65=least miserable, 1=most miserable). The index measures the unemployment rate coupled with the inflation rate. Bloomberg commented that "The least miserable country is once again Thailand—in large part due to its unique way of calculating employment..." Other ASEAN nations were ranked: Singapore, 64; Malaysia, 55; Vietnam, 54; Philippines, 37; Indonesia, 23. Bloomberg's Misery Index 2016 ranked Thailand 63 of 63 nations (63=least miserable, 1=most miserable). The index measures the unemployment rate coupled with the inflation rate.
Sources: en.wikipedia.org
=== Surgical techniques === The effectiveness of a rhinoplastic reconstruction of the external nose derives from the contents of the surgeon's armamentarium of skin-flap techniques applicable to correcting defects of the nasal skin and of the mucosal lining; some management techniques are the bilobed flap, the nasolabial flap, the paramedian forehead flap, and the septal mucosal flap.
=== Methylene blue value of fine aggregate === The methylene blue value is defined as the number of milliliters of standard methylene blue solution decolorized 0.1 g of activated carbon (dry basis). Methylene blue value reflects the amount of clay minerals in aggregate samples. In materials science, methylene blue solution is successively added to fine aggregate which is being agitated in water. The presence of free dye solution can be checked with a stain test on a filter paper.
=== Research applications === Polyphenol oxidases (PPOs): These include both catechol oxidases and tyrosinases. In additional to research, PPOs have also found applications as biocatalysts. Cystatins are proteins that inhibit cysteine proteases. Research are ongoing to evaluate the potential of using cystatins in crop protection to control herbivorous pests and pathogens.
=== One-dimensional nanostructures === The smallest possible crystalline wires with cross-section as small as a single atom can be engineered in cylindrical confinement. Carbon nanotubes, a natural semi-1D nanostructure, can be used as a template for synthesis. Confinement provides mechanical stabilization and prevents linear atomic chains from disintegration; other structures of 1D nanowires are predicted to be mechanically stable even upon isolation from the templates.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.